Biomarkers of tolerance in kidney transplantation: Are we predicting tolerance or response to immunosuppressive treatment?

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023001%3A_____%2F16%3A00060108" target="_blank" >RIV/00023001:_____/16:00060108 - isvavai.cz</a>

Result on the web

<a href="http://onlinelibrary.wiley.com/doi/10.1111/ajt.13932/epdf" target="_blank" >http://onlinelibrary.wiley.com/doi/10.1111/ajt.13932/epdf</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1111/ajt.13932" target="_blank" >10.1111/ajt.13932</a>

Result language

angličtina

Original language name

Biomarkers of tolerance in kidney transplantation: Are we predicting tolerance or response to immunosuppressive treatment?

Original language description

We and others have previously described signatures of tolerance in kidney transplantation showing the differential expression of B cell-related genes and the relative expansions of B cell subsets. However, in all of these studies, the index group-namely, the tolerant recipients-were not receiving immunosuppression (IS) treatment, unlike the rest of the comparator groups. We aimed to assess the confounding effect of these regimens and develop a novel IS-independent signature of tolerance. Analyzing gene expression in three independent kidney transplant patient cohorts (232 recipients and 14 tolerant patients), we have established that the expression of the previously reported signature was biased by IS regimens, which also influenced transitional B cells. We have defined and validated a new gene expression signature that is independent of drug effects and also differentiates tolerant patients from healthy controls (cross-validated area under the receiver operating characteristic curve [AUC] = 0.81). In a prospective cohort, we have demonstrated that the new signature remained stable before and after steroid withdrawal. In addition, we report on a validated and highly accurate gene expression signature that can be reliably used to identify patients suitable for IS reduction (approximately 12% of stable patients), irrespective of the IS drugs they are receiving. Only a similar approach will make the conduct of pilot clinical trials for IS minimization safe and hence allow critical improvements in kidney posttransplant management.

Czech name

—

Czech description

—

Type

J_x - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)

CEP classification

FE - Other fields of internal medicine

OECD FORD branch

—

Project

—

Continuities

N - Vyzkumna aktivita podporovana z neverejnych zdroju

Publication year

2016

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

American journal of transplantation

ISSN

1600-6135

e-ISSN

—

Volume of the periodical

16

Issue of the periodical within the volume

12

Country of publishing house

US - UNITED STATES

Number of pages

15

Pages from-to

3443-3457

UT code for WoS article

000388208600016

EID of the result in the Scopus database

—